Income Statement Proteome Sciences plc
Stocks
PRM
GB0003104196
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.800 GBX | 0.00% |
|
0.00% | -28.00% |
| 07-21 | WINNERS & LOSERS: Harvest Minerals surges on Brazil portfolio takeover | AN |
| 07-20 | WINNERS & LOSERS: Sunrise announces new metals project in Nevada | AN |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 5.13M | 7.78M | 5.03M | 4.89M | 3.76M | |||||
Total Revenues | 5.13M | 7.78M | 5.03M | 4.89M | 3.76M | |||||
Cost of Goods Sold, Total | 2.17M | 3.01M | 3.38M | 4.22M | 3.84M | |||||
Gross Profit | 2.96M | 4.77M | 1.65M | 670K | -81K | |||||
Selling General & Admin Expenses, Total | 2.55M | 2.64M | 2.78M | 2.19M | 1.66M | |||||
Depreciation & Amortization - (IS) | - | 397K | 484K | 837K | 926K | |||||
Other Operating Expenses, Total | 2.55M | 3.04M | 3.27M | 3.02M | 2.58M | |||||
Operating Income | 412K | 1.73M | -1.62M | -2.35M | -2.67M | |||||
Interest Expense, Total | -294K | -473K | -797K | -895K | -925K | |||||
Interest And Investment Income | - | - | - | - | - | |||||
Net Interest Expenses | -294K | -473K | -797K | -895K | -925K | |||||
Other Non Operating Income (Expenses) | - | - | - | 0 | - | |||||
EBT, Excl. Unusual Items | 118K | 1.26M | -2.42M | -3.25M | -3.59M | |||||
EBT, Incl. Unusual Items | 118K | 1.26M | -2.42M | -3.25M | -3.59M | |||||
Income Tax Expense | 46K | -70K | 25K | 158K | -530K | |||||
Earnings From Continuing Operations | 72K | 1.32M | -2.44M | -3.41M | -3.06M | |||||
Net Income to Company | 72K | 1.32M | -2.44M | -3.41M | -3.06M | |||||
Net Income - (IS) | 72K | 1.32M | -2.44M | -3.41M | -3.06M | |||||
Net Income to Common Incl Extra Items | 72K | 1.32M | -2.44M | -3.41M | -3.06M | |||||
Net Income to Common Excl. Extra Items | 72K | 1.32M | -2.44M | -3.41M | -3.06M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0 | 0 | -0.01 | -0.01 | -0.01 | |||||
Basic EPS - Continuing Operations | 0 | 0 | -0.01 | -0.01 | -0.01 | |||||
Basic Weighted Average Shares Outstanding | 295M | 295M | 295M | 295M | 295M | |||||
Net EPS - Diluted | 0 | 0 | -0.01 | -0.01 | -0.01 | |||||
Diluted EPS - Continuing Operations | 0 | 0 | -0.01 | -0.01 | -0.01 | |||||
Diluted Weighted Average Shares Outstanding | 302M | 309M | 295M | 295M | 305M | |||||
Normalized Basic EPS | 0 | 0 | -0.01 | -0.01 | -0.01 | |||||
Normalized Diluted EPS | 0 | 0 | -0.01 | -0.01 | -0.01 | |||||
Supplemental Items | ||||||||||
EBITDA | 452K | 1.83M | -1.5M | -2.2M | -2.49M | |||||
EBITA | 412K | 1.73M | -1.62M | -2.35M | -2.67M | |||||
EBIT | 412K | 1.73M | -1.62M | -2.35M | -2.67M | |||||
EBITDAR | 482K | 1.85M | -1.49M | -2.19M | -2.48M | |||||
Total Revenues (As Reported) | 5.13M | 7.78M | 5.03M | 4.89M | 3.76M | |||||
Effective Tax Rate - (Ratio) | 38.98 | -5.58 | -1.03 | -4.86 | 14.76 | |||||
Current Foreign Taxes | - | 156K | 160K | 158K | -173K | |||||
Total Current Taxes | - | 156K | 160K | 158K | -173K | |||||
Normalized Net Income | 73.75K | 784K | -1.51M | -2.03M | -2.24M | |||||
Interest on Long-Term Debt | 15K | 37K | 57K | 97K | 81K | |||||
Non-Cash Pension Expense | 24.73K | -139K | -29.57K | 17.1K | 80.75K | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 2.55M | 2.64M | 2.78M | 2.19M | 1.66M | |||||
Research And Development Expense From Footnotes | 287K | 376K | 637K | 606K | 261K | |||||
Net Rental Expense, Total | 30K | 12K | 9K | 9K | 9K | |||||
Imputed Operating Lease Interest Expense | 6.21K | 3.85K | 4.52K | 4.6K | 4.4K | |||||
Imputed Operating Lease Depreciation | 23.79K | 8.15K | 4.48K | 4.4K | 4.6K | |||||
Stock-Based Comp., Other (Total) | 570K | 303K | 218K | 40K | 18K | |||||
Total Stock-Based Compensation | 570K | 303K | 218K | 40K | 18K |
- Stock Market
- Stocks
- PRM Stock
- Financials Proteome Sciences plc
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















